Menu
The key stages of the project were numerous, from research to development :
by Swedish neurophysiologist Dr. Yngve Zotterman. They were until then mainly known to be involved in the pleasant sensations of touch.
« MOLECULAR AND CELLULAR MECHANISM » by Dr. Aziz Moqrich at the IBDM & Dr. Stéphane Gaillard who joined the team.
for an innovative treatment against pain
for the use of TAFA4 as an antalgic drug.
after a meeting with Eric Schettini
Tafalgie Therapeutics finalizing the founders’ round table with the arrival of Laurent Labatut and the establishment of a support team
with « SATT Sud-Est »
is earned by Prof. Ardem Patapoutian and Prof. David Julius, for their research on temperature- and touch-sensitive receptors.
with pre-clinical studies, R&D activités, regulatory activities, Scientific Advisory Board, and search for financial support
“An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage »
IASP 2020 – International Association for the Study of Pain
Discover the key milestones in the progress of the Tafalgie project
TAFALGIE THERAPEUTICS is a simplified joint-stock biotechnology company, Spin-off of the IBDM laboratory (AMU/CNRS).
The society is created IN OCTOBER 2020 BY FOUR FOUNDERS having complementary and internationally recognized expertise in the fields of neurosciences, research, finances and industrial development.
